Skip to main content

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing a unique drug to treat concussion, has announced that, in order to keep its focus, it has dissolved its sports advisory board. According to the announcement, the sports board has been a distraction for the company, and in order to continue to focus on its concussion drug-development program, the company made the decision to disband the board. “The sports advisory members have been outspoken advocates for concussion prevention and for the importance of finding responsible treatments,” the company stated in the press release. “We created the advisory board to increase awareness of our mission to bring a much-needed pharmaceutical for a condition that currently has no FDA-approved treatment. We have recently completed a phase I human trial where our drug was proven to be safe and well tolerated. We are excited about the potential of initiating a phase II trial to determine the efficacy and safety of the drug in concussed patients. The press has misrepresented Odyssey Health, Inc. Odyssey has never directly or indirectly received money from state or federal government sources to fund the drug development. Odyssey is not involved in any litigation. Odyssey Health Inc. purchased the intellectual property and rights to the drug on March 1, 2021. The money to fund the drug development has come from accredited investors. . . The company will remain committed to bringing products to market that provide a solution to unmet medical needs.

To view the full press release, visit

About Odyssey Health Inc. 

Odyssey Health is a medical company with a focus in the area of life-saving medical solutions. Odyssey’s corporate mission is to create, acquire and develop distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity. For more information about the company, please visit

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office

InvestorWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.